目的 探讨肝癌经皮射频消融（PRFA）治疗后完全消融（CR）率的影响因素。方法 选择接受超声引导下PRFA治疗的肝癌患者60例作为研究对象。根据术后超声造影的结果将患者分为CR组和不完全消融（ICR）组。分别记录不同因素影响下的消融病灶数及CR率并比较两组患者各因素的差异。通过进一步的多因素logistic回归方法分析PRFA术后肿瘤CR率的独立影响因素。结果 PRFA治疗后共消融94个病灶,总CR率为91.26%。通过比较,发现肿瘤类型、肿瘤是否位于特殊解剖位置、肿瘤最大直径、消融范围、消融能量、中心治疗温度与肿瘤的CR率明显相关（P<0.05）。进一步的多因素logistic回归结果表明：肿瘤类型（P=0.024）、肿瘤是否位于特殊解剖位置（P=0.031）、肿瘤最大直径（P=0.001）、消融范围（P<0.001）、消融能量（P=0.003）、中心治疗温度（P=0.009）是影响PRFA术后肿瘤CR率的独立影响因素。结论 肿瘤类型、肿瘤是否位于特殊解剖位置、肿瘤最大直径、消融范围、消融能量和中心治疗温度对PRFA术后肿瘤的CR率有重要影响。
Objective To explore the factors influencing the complete response (CR) rate of liver cancer after percutaneous radiofrequency ablation (PRFA). Methods A total of 60 patients with liver cancer treated with ultrasound-guided PRFA were recruited from our hospital. According to the postoperative results of contrast-enhanced ultrasound, the patients were divided into CR group and in-complete response (ICR) group. The ablation number of lesions and CR rate under the influence of different factors were recorded and the differences of each factor between the two groups were compared. Further multiple logistic regression was used to analyze the independent influencing factors of tumor CR rate after PRFA. Results A total of 94 lesions were completely ablated after PRFA treatment, and the total CR rate was 91.26%. Tumor type, special anatomical position, maximum tumor diameter, ablative margin, ablation energy, and central temperature were significantly correlated with the CR rate of tumor (P<0.05). Further multiple logistic regression results showed that tumor type (P=0.024), special anatomical position (P=0.031), maximum tumor diameter (P=0.001), ablative margin (P<0.001), ablation energy (P=0.003) and central temperature of tumor (P=0.009) were independent influencing factors of tumor CR rate after PRFA. Conclusion Tumor type, special anatomic location, maximum tumor diameter,ablative margin, ablation energy, and central temperature of tumor have important effects on CR rate of liver cancer after PRFA.
[1] Torre L A, Bray F, Siegel R L, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108.
[2] Chen W, Zheng R, Baade P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
[3] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华消化外科杂志,2017,16(7):635-647.
[4] 周勇旭, 陆朝阳, 潘博, 等. 射频消融术治疗肝癌的研究新进展[J]. 现代生物医学进展, 2015, 15(05):991-994.
[5] Dupré A, Gagnière J, Chen Y, et al.Management of synchronous colorectal liver metastases[J]. Bull Cancer, 2013, 100(4):363-371.
[6] 练远书, 杨浩. 经皮射频消融与手术切除治疗小肝癌的临床效果对比[J]. 临床医学研究与实践, 2016, 1(06):16+18.
[7] Lin Y H, Chiou Y Y, Chou Y H, et al.Radiofrequency ablation for recurrent hepatocellular carcinoma in postresectional patients: prognostic factors analysis[J]. Eur J Gastroenterol Hepatol, 2011,23(12):1239-1244.
[8] 任炜,杨薇.射频消融治疗复发性肝癌疗效及预后因素分析[J]. 介入放射学杂志, 2015,24(10):923-927.
[9] 霍峰. 超声引导射频消融治疗肝脏恶性肿瘤286例肿瘤残留危险因素研究[J]. 黑龙江科学, 2015,6(12):22-23.
[10] Fonseca A Z, Santin S, Gomes L G, et al.Complications of radiofrequency ablation of hepatic tumors: frequency and risk factors[J]. World J Hepatol, 2014,6(3):107-113.
[11] 段浩朋, 赵永福. 经皮肝穿刺射频消融治疗临近肝脏大血管肝癌的安全性及疗效分析[J].河南医学研究, 2016,25(4):638-640.
[12] 徐建波, 祁付珍, 许刚,等. 原发性中小肝癌手术与射频消融治疗的疗效分析[J]. 现代肿瘤医学, 2013,21(8):1822-1825.
[13] 李蕊利, 万娟. 原发性肝癌射频消融预后的影响因素分析[J]. 现代肿瘤医学, 2015,23(20):2970-2972.
[14] 魏涛. 超声引导经皮射频消融治疗肝癌的疗效及影响疗效的因素研究[J]. 齐齐哈尔医学院学报, 2016, 37(5):605-606.
[15] Ke S, Ding X M, Qian X J, et al.Radiofrequency ablation of hepatocellular carcinoma sized > 3 and ≤ 5 cm: is ablative margin of more than 1 cm justified?[J]. World J Gastroenterol, 2013,19(42):7389-7398.
